Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data
Open Access
- 18 February 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 225 (11), 1876-1885
- https://doi.org/10.1093/infdis/jiab101
Abstract
Background Given the persistently high global burden of tuberculosis, effective and shorter treatment options are needed. We explored the relationship between relapse and treatment length as well as interregimen differences for 2 novel antituberculosis drug regimens using a mouse model of tuberculosis infection and mathematical modeling. Methods Mycobacterium tuberculosis-infected mice were treated for up to 13 weeks with bedaquiline and pretomanid combined with moxifloxacin and pyrazinamide (BPaMZ) or linezolid (BPaL). Cure rates were evaluated 12 weeks after treatment completion. The standard regimen of isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE) was evaluated as a comparator. Results Six weeks of BPaMZ was sufficient to achieve cure in all mice. In contrast, 13 weeks of BPaL and 24 weeks of HRZE did not achieve 100% cure rates. Based on mathematical model predictions, 95% probability of cure was predicted to occur at 1.6, 4.3, and 7.9 months for BPaMZ, BPaL, and HRZE, respectively. Conclusion This study provides additional evidence for the treatment-shortening capacity of BPaMZ over BPaL and HRZE. To optimally use preclinical data for predicting clinical outcomes, and to overcome the limitations that hamper such extrapolation, we advocate bundling of available published preclinical data into mathematical models. By combining the evaluation of treatment efficacy of anti-tuberculosis drug regimens in a mouse tuberculosis infection model with mathematical modeling, it was found that BPaMZ had a higher treatment-shortening potential than BPaL, compared to the standard HRZE regimen.Keywords
Funding Information
- Australia’s Department of Foreign Affairs and Trade
- Bill and Melinda Gates Foundation (OPP1129600)
- Germany’s Federal Ministry of Education and Research through the KfW
- National Institute of Allergy and Infectious Disease
- the Netherlands Ministry of Foreign Affairs
- United Kingdom Department for International Development
- US Agency for International Development
This publication has 40 references indexed in Scilit:
- Randomized Clinical Trial of Thrice-Weekly 4-Month Moxifloxacin or Gatifloxacin Containing Regimens in the Treatment of New Sputum Positive Pulmonary Tuberculosis PatientsPLOS ONE, 2013
- Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and XposeCPT: Pharmacometrics & Systems Pharmacology, 2013
- Dose-Ranging Comparison of Rifampin and Rifapentine in Two Pathologically Distinct Murine Models of TuberculosisAntimicrobial Agents and Chemotherapy, 2012
- Evaluation of a Mouse Model of Necrotic Granuloma Formation Using C3HeB/FeJ Mice for Testing of Drugs against Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2012
- Importance of Confirming Data on the In Vivo Efficacy of Novel Antibacterial Drug Regimens against Various Strains of Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2012
- Tissue concentrations: do we ever learn?Journal of Antimicrobial Chemotherapy, 2007
- Synergistic Activity of R207910 Combined with Pyrazinamide against Murine TuberculosisAntimicrobial Agents and Chemotherapy, 2007
- OPC-67683, a Nitro-Dihydro-Imidazooxazole Derivative with Promising Action against Tuberculosis In Vitro and In MicePLoS Medicine, 2006
- Combination Chemotherapy with the Nitroimidazopyran PA-824 and First-Line Drugs in a Murine Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2006
- Moxifloxacin-containing Regimens of Reduced Duration Produce a Stable Cure in Murine TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2004